Drug Trial Radar · NCT02682927
A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
262
Actual
Start
Jan 15, 2016
Primary completion
Jul 29, 2020
Study completion Jul 29, 2020
Sponsor
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study 1 and Study 3 are the prospective, merged analyses of 2 identical double-blind, placebo-controlled studies, ZX008-1501 and ZX008-1502, to assess the efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric and young adult subjects with Dravet syndrome. Study 1501 and Study 1502 were conducted in parallel; Study 1501 was conducted at approximately 30 study sites in North America; Study 1502 was conducted at approximately 30 study sites in Europe, Asia and Australia. Upon completion of the Baseline Period after initial Screening and Baseline charting of seizure frequency, subjects who qualified for the studies were randomized (1:1:1) in a double-blind manner to receive either 1 of 2 doses of ZX008 (0.2 mg/kg/day or 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization was stratified by age group (\< 6 years, ≥6 to 18 years) to achieve balance across treatment arms, with the target of 25% of subjects in each age group. All subjects were titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects continued treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study underwent a 2-week taper, unless they enrolled in a follow-on study. Subjects were followed for post-study safety monitoring.
Conditions
- Dravet Syndrome
- Seizure Disorder
Interventions
ZX008 (Fenfluramine Hydrochloride)Drug
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
Matching PlaceboDrug
Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to PlaceboTime frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Locations
55 sites in 11 countries. Site status is shown where the registry gives one.
Phoenix Children's
Phoenix, Arizona
Center for Neurosciences - Tucson
Tucson, Arizona
Rady Children's Hospital San Diego
San Diego, California
University of California San Francisco
San Francisco, California
The Children's Hospital Colorado
Aurora, Colorado
NW FL Clinical Research Group, LLC
Gulf Breeze, Florida
Miami Children's Hospital Brain Institute
Miami, Florida
Neurology and Epilepsy Research Center
Orlando, Florida
Panda Neurology
Atlanta, Georgia
Children's Hospital of Chicago
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Boston Children's Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Saint Barnabas Medical Center
Livingston, New Jersey
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Cook Children's Medical Center
Fort Worth, Texas
University of Utah
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
MultiCare Institute for Research & Innovation
Tacoma, Washington
Melbourne Brain Centre Austin Hospital
Melbourne, Australia
Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital
South Brisbane, Australia
The Children's Hospital Westmead Dept. of Neurology and Neurosurgery
Westmead, Australia
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Canada
British Columbia Children's Hospital BCCH
Vancouver, British Columbia, Canada
Danish National Epilepsy Centre
Dianalund, Denmark
French Ref centre Necker Hospital Paris
Paris, France
Epilepsiezentrum / Neuropädiatrie Hedwig-von-Rittberg-Zentrum Für Kinder und Jugendliche
Berlin, Germany
Krankenhaus Mara Epilepsie-Zentrum Bethel
Bielefeld, Germany
Epilepsiezentrum Freiburg
Freiburg im Breisgau, Germany
Universitaetsklinikum Jena Klinik fuer Kinder- und Jugendmedizin Neuropaediatrie
Jena, Germany
Klinik für Neuropädiatrie Universitätsklinikum Schleswig Holstein Campus Kiel
Kiel, Germany
Kleinwachau Saechsisches Epilepsiezentrum Radeberggemeinnuetzige GmbH
Radeberg, Germany
Universitaetsklinik fuer Kinder- und Jugendmedizin Abteilung III
Tübingen, Germany
Schoen Klinik Vogtareuth Neuropaediatrie und Neurologische Rehabilitation, Epilepsiezentrum fuer Kinder und Jugendlische,Tagesklinik fuer Neuropaediatrie
Vogtareuth, Germany
AOU Anna Meyer
Florence, Italy
Istituto Pediatrico Giannina Gaslini Dipartimento di Neurologia
Genova, Italy
A.O Carlo Poma
Mantua, Italy
Instituto Neurologica Carlo Besta
Milan, Italy
Ospedale Fatebenefratelli e Oftalmico
Milan, Italy
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.